Philochem Grants RayzeBio Global Rights to OncoACP3 for Prostate Cancer
Switzerland-based Philochem AG, a wholly-owned subsidiary of the Philogen Group (BIT: PHIL), announced a licensing...
RayzeBio
BMS Regains Exclusive Rights to ABZ-706 in Greater China
Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a...
Ablaze Pharma Charts Path for GPC3-Targeted Polypeptide with RayzeBio Partnership
Ablaze Pharma, a Chinese biopharmaceutical company, has announced its development plan for a GPC3-targeted polypeptide...